Working... Menu

An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis ((HOPE-1))

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03229252
Recruitment Status : Recruiting
First Posted : July 25, 2017
Last Update Posted : April 25, 2019
Information provided by (Responsible Party):
Spyryx Biosciences, Inc.

Brief Summary:
28-Day double-blinded efficacy and safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: Placebo Inhalation Solution Drug: SPX-101 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)
Actual Study Start Date : August 1, 2017
Estimated Primary Completion Date : May 15, 2019
Estimated Study Completion Date : May 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo Inhalation solution twice daily for 28 days.
Drug: Placebo Inhalation Solution
Normal Saline Inhalation Solution

Experimental: SPX-101 Low Dose
Inhalation solution twice daily for 28 days.
Drug: SPX-101
SPX-101 Inhalation Solution

Experimental: SPX-101 High Dose
Inhalation solution twice daily for 28 days.
Drug: SPX-101
SPX-101 Inhalation Solution

Primary Outcome Measures :
  1. Change in percent predicted FEV1 [ Time Frame: Baseline and Day 28 ]

Secondary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: Day 1 through Day 28 ]
  2. Change from baseline through Day 28 in clinical laboratory tests [ Time Frame: Day 1 through Day 28 ]
    Chemistry, Hematology, Urinalysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of CF
  • ppFEV1 between 50.0% and 80.0%
  • Stable CF Lung Disease
  • Males and non-pregnant, non-lactating females

Exclusion Criteria:

  • Significant unstable co-morbidities within 28 days of screening
  • Has received an investigational drug within 28 days of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03229252

Layout table for location contacts
Contact: Lynn Smiley, MD 919-899-9399

Layout table for location information
Canada, Alberta
University of Calgary Heritage Medical Research Center Recruiting
Calgary, Alberta, Canada, T2N 1N4
Contact: Michael Parkins, MD         
Canada, Ontario
Ottawa Hospital Research Institute/Institut de Recherche de l'Hospital d'Ottawa Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Shawn Aaron, MD         
Saint Michael's Hospital Recruiting
Toronto, Ontario, Canada, M5B1W8
Contact: Elizabeth Tullis, MD         
Canada, Quebec
McGill University Health Center Not yet recruiting
Montréal, Quebec, Canada
Contact: Larry Lands, MD, PhD         
Centre Hospitalier Universitaire Brest Recruiting
Roscoff, Bretagne, France
Contact: Sophie Ramel, MD         
CHU de Rouen Recruiting
Rouen, Haute-Normandie, France
Contact: Stéphane Dominique, MD         
CHU de Montpellier Recruiting
Montpellier, Languedoc-Roussillon, France
Contact: Raphaël Chiron, MD         
CHU de Angers Recruiting
Angers, Pays De La Loire, France
Contact: Christine Person-Tacnet, MD         
Hopital Pasteur Recruiting
Nice, Provence Alpes Cote D'azur, France
Contact: Sylvie Leroy, MD         
Hospices Civils de Lyon (HCL) Recruiting
Pierre Bénite, Rhone-Alpes, France
Contact: Isabelle Durieu, MD         
Assistance Publique-Hôpitaux de Paris Hôpital Cochin Recruiting
Paris, France
Contact: Isabelle Fajac, MD         
Istituto Giannina Gaslini Ospedale Pediatrico Recruiting
Genoa, Italy
Contact: Federico Cresta, MD         
Hospital de Santa Maria Recruiting
Lisbon, Portugal
Contact: Pilar Azevedo, MD         
United Kingdom
Belfast Health and Social Care Trust Recruiting
Belfast, United Kingdom
Contact: Damian Downey, MD         
Heart of England NHS Foundation Trust Recruiting
Birmingham, United Kingdom
Contact: Edward Nash, MD         
University Hospitals Bristol NHS Foundation Trust Recruiting
Bristol, United Kingdom
Contact: Nicholas Bell, MD         
Western General Hospital - NHS Lothian Recruiting
Edinburgh, United Kingdom
Contact: Alastair Innes, MD         
Royal Devon and Exeter NHS Foundation Trust Recruiting
Exeter, United Kingdom
Contact: Nicholas Withers, MD         
NHS Greater Glasgow and Clyde Recruiting
Glasgow, United Kingdom
Contact: Gordon MacGregor, MD         
The Leeds Teaching Hospitals NHS Trust Recruiting
Leeds, United Kingdom
Contact: Daniel Peckham, MD         
Liverpool Heart and Chest Hospital NHS Foundation Trust Recruiting
Liverpool, United Kingdom
Contact: Martin Ledson, MD         
Barts Health NHS Trust Saint Bartholomews Hospital Recruiting
London, United Kingdom
Contact: Nadia Shafi, MD         
Royal Brompton and Harefield NHS Foundation Trust Recruiting
London, United Kingdom
Contact: Nicholas Simmonds         
University Hospital of South Manchester NHS Foundation Trust Recruiting
Manchester, United Kingdom
Contact: Andrew Jones, MD         
Newcastle Upon Tyne Hospitals Recruiting
Newcastle-upon-Tyne, United Kingdom
Contact: Simon Doe, MD         
Nottingham University Hospitals NHS Trust Recruiting
Nottingham, United Kingdom
Contact: Helen Barr, MD         
Sponsors and Collaborators
Spyryx Biosciences, Inc.

Layout table for additonal information
Responsible Party: Spyryx Biosciences, Inc. Identifier: NCT03229252     History of Changes
Other Study ID Numbers: SPX-101-CF-201
First Posted: July 25, 2017    Key Record Dates
Last Update Posted: April 25, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pharmaceutical Solutions